Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of type 2 diabetes
3.2.1.2 High patient preference for oral medications
3.2.1.3 Increasing combination therapy trend
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of other antidiabetic drugs
3.2.2.2 Side effects associated with DPP-4 inhibitors
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Sitagliptin
5.3 Saxagliptin
5.4 Linagliptin
5.5 Alogliptin
5.6 Vildagliptin
5.7 Other drug types
Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Branded
6.3 Generic
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca plc
9.2 Bristol Myers Squibb Company
9.3 Boehringer Ingelheim International GmbH
9.4 Eli Lilly and Company
9.5 Merck & Co., Inc.
9.6 Mitsubishi Tanabe Pharma Corporation
9.7 Novartis AG
9.8 Pfizer, Inc.
9.9 Takeda Pharmaceuticals Company Limited
9.10 Sanofi
9.11 Sanwa Kagaku Kenkyusho Co., Ltd.
